Featured Research

from universities, journals, and other organizations

Significant discrepancies between FISH, IHC results for ALK testing

Date:
February 24, 2014
Source:
International Association for the Study of Lung Cancer
Summary:
Routine testing with both fluorescent in situ hybridization and immunohistochemistry may enhance the detection of ALK-positive non-small cell lung cancer, new research suggests. Accurate determination of ALK-positive tumors is necessary to identify patients with advanced NSCLC who are most likely to benefit from targeted therapy with an ALK inhibitor. The study also demonstrated that systematic testing of NSCLC by both FISH and IHC is feasible in routine practice.

The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC). Accurate determination of ALK-positive tumors is necessary to identify patients with advanced NSCLC who are most likely to benefit from targeted therapy with an ALK inhibitor.

The discovery of ALK rearrangement in about 1% to 7% of NSCLCs led to the development of ALK inhibitors, such as crizotinib, which have significantly improved treatment response among people with ALK-positive NSCLC. FISH with break-apart probes is currently the only approved test for the detection of ALK positivity in NSCLC, but this technique may not be available or feasible in all institutions. IHC, which is more affordable and accessible than FISH, has been found to be reliable as a screening tool, but interpretation of its results have not been standardized. Researchers continue to explore the optimal testing process for identifying ALK-positive NSCLCs.

Parallel testing with both FISH and IHC on 3,234 NSCLCs led to the identification of 150 tumors that were ALK positive by either test. The results of FISH and IHC were discordant in 80 of these tumors. As such, the use of FISH or IHC alone would have missed approximately 25% of ALK-positive cases. The findings of the study are published in the March issue of the International Association for the Study of Lung Cancer's journal, the Journal of Thoracic Oncology (JTO).

Most discordant results were FISH-positive/IHC-negative (36 cases); FISH-negative/IHC-positive results were found in 19 cases, and FISH-noncontributive/IHC-positive results were found in 15 cases. Preliminary data from 44 evaluable patients showed that treatment with an ALK inhibitor was associated with a high response rate, with response noted among patients who had tumors with discordant results (either FISH-positive/IHC-negative or FISH-negative/IHC-positive).

"Data on crizotinib response in patients who have been diagnosed differently by FISH and IHC are still preliminary. Thus, until large-scale studies in patients under therapy with crizotinib determine which testing is the most relevant to predict responses to ALK inhibition, our data support the need to routinely perform both analyses because of the difficulty in detecting the chimeric ALK protein in NSCLC and the presence of false-negative cases for each method," says lead author Florian Cabillic, PharMD, PhD, Université de Rennes, Rennes, France.

The study also demonstrated that systematic testing of NSCLC by both FISH and IHC is feasible in routine practice. In addition, the findings indicate that performing FISH routinely on all NSCLC specimens may require an automated process at various stages of the analysis.


Story Source:

The above story is based on materials provided by International Association for the Study of Lung Cancer. Note: Materials may be edited for content and length.


Journal Reference:

  1. Florian Cabillic, Audrey Gros, Frédéric Dugay, Hugues Begueret, Laura Mesturoux, Dan Cristian Chiforeanu, Leila Dufrenot, Vincent Jauffret, Dominique Dachary, Romain Corre, Alexandra Lespagnol, Gwendoline Soler, Julien Dagher, Véronique Catros, Michèle Le Calve, Jean-Philippe Merlio, Marc-Antoine Belaud-Rotureau. Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances. Journal of Thoracic Oncology, 2014; 9 (3): 295 DOI: 10.1097/JTO.0000000000000072

Cite This Page:

International Association for the Study of Lung Cancer. "Significant discrepancies between FISH, IHC results for ALK testing." ScienceDaily. ScienceDaily, 24 February 2014. <www.sciencedaily.com/releases/2014/02/140224124117.htm>.
International Association for the Study of Lung Cancer. (2014, February 24). Significant discrepancies between FISH, IHC results for ALK testing. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2014/02/140224124117.htm
International Association for the Study of Lung Cancer. "Significant discrepancies between FISH, IHC results for ALK testing." ScienceDaily. www.sciencedaily.com/releases/2014/02/140224124117.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Predicting Heart Transplant Rejection With a Blood Test

Predicting Heart Transplant Rejection With a Blood Test

Ivanhoe (Aug. 27, 2014) — Now a new approach to rejection of donor organs could change the way doctors predict transplant rejection…without expensive, invasive procedures. Video provided by Ivanhoe
Powered by NewsLook.com
Better Braces That Vibrate

Better Braces That Vibrate

Ivanhoe (Aug. 27, 2014) — The length of time you have to keep your braces on could be cut in half thanks to a new device that speeds up the process. Video provided by Ivanhoe
Powered by NewsLook.com
Smartphone App Tracks Your Heart Rate

Smartphone App Tracks Your Heart Rate

Ivanhoe (Aug. 27, 2014) — A new app that can track your heart rate 24/7 is available for download in your app store and its convenience could save your life. Video provided by Ivanhoe
Powered by NewsLook.com
Stroke in Young Adults

Stroke in Young Adults

Ivanhoe (Aug. 27, 2014) — A stroke can happen at any time and affect anyone regardless of age. This mother chose to give her son independence and continue to live a normal life after he had a stroke at 18 years old. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins